These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 24632142

  • 1. Reexamination of aspartoacylase: is this human enzyme really a glycoprotein?
    Wang Q, Viola RE.
    Arch Biochem Biophys; 2014 Apr 15; 548():66-73. PubMed ID: 24632142
    [Abstract] [Full Text] [Related]

  • 2. Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease.
    Le Coq J, An HJ, Lebrilla C, Viola RE.
    Biochemistry; 2006 May 09; 45(18):5878-84. PubMed ID: 16669630
    [Abstract] [Full Text] [Related]

  • 3. Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
    Herga S, Berrin JG, Perrier J, Puigserver A, Giardina T.
    FEBS Lett; 2006 Oct 30; 580(25):5899-904. PubMed ID: 17027983
    [Abstract] [Full Text] [Related]

  • 4. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
    Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN.
    Proc Natl Acad Sci U S A; 2007 Jan 09; 104(2):456-61. PubMed ID: 17194761
    [Abstract] [Full Text] [Related]

  • 5. Purification and preliminary characterization of brain aspartoacylase.
    Moore RA, Le Coq J, Faehnle CR, Viola RE.
    Arch Biochem Biophys; 2003 May 01; 413(1):1-8. PubMed ID: 12706335
    [Abstract] [Full Text] [Related]

  • 6. Mutational analysis of aspartoacylase: implications for Canavan disease.
    Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA.
    Brain Res; 2007 May 07; 1148():1-14. PubMed ID: 17391648
    [Abstract] [Full Text] [Related]

  • 7. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
    Kaul R, Gao GP, Balamurugan K, Matalon R.
    Nat Genet; 1993 Oct 07; 5(2):118-23. PubMed ID: 8252036
    [Abstract] [Full Text] [Related]

  • 8. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
    Wijayasinghe YS, Pavlovsky AG, Viola RE.
    Biochemistry; 2014 Aug 05; 53(30):4970-8. PubMed ID: 25003821
    [Abstract] [Full Text] [Related]

  • 9. Murine aspartoacylase: cloning, expression and comparison with the human enzyme.
    Namboodiri MA, Corigliano-Murphy A, Jiang G, Rollag M, Provencio I.
    Brain Res Mol Brain Res; 2000 May 05; 77(2):285-9. PubMed ID: 10837925
    [Abstract] [Full Text] [Related]

  • 10. Relationship between enzyme properties and disease progression in Canavan disease.
    Zano S, Wijayasinghe YS, Malik R, Smith J, Viola RE.
    J Inherit Metab Dis; 2013 Jan 05; 36(1):1-6. PubMed ID: 22850825
    [Abstract] [Full Text] [Related]

  • 11. A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity.
    Di Pietro V, Gambacurta A, Amorini AM, Finocchiaro A, D'Urso S, Ceccarelli L, Tavazzi B, Giardina B, Lazzarino G.
    Clin Biochem; 2008 May 05; 41(7-8):611-5. PubMed ID: 18280251
    [Abstract] [Full Text] [Related]

  • 12. Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.
    Kocak A, Yildiz M.
    J Mol Graph Model; 2017 Jun 05; 74():44-53. PubMed ID: 28349879
    [Abstract] [Full Text] [Related]

  • 13. N-glycosylation influences the latency and catalytic properties of mammalian purple acid phosphatase.
    Wang Y, Norgård M, Andersson G.
    Arch Biochem Biophys; 2005 Mar 01; 435(1):147-56. PubMed ID: 15680916
    [Abstract] [Full Text] [Related]

  • 14. Canavan disease: molecular basis of aspartoacylase deficiency.
    Kaul R, Gao GP, Balamurugan K, Matalon R.
    J Inherit Metab Dis; 1994 Mar 01; 17(3):295-7. PubMed ID: 7528829
    [No Abstract] [Full Text] [Related]

  • 15. Cloning and characterization of a novel amidase from Paracoccus sp. M-1, showing aryl acylamidase and acyl transferase activities.
    Shen W, Chen H, Jia K, Ni J, Yan X, Li S.
    Appl Microbiol Biotechnol; 2012 May 01; 94(4):1007-18. PubMed ID: 22101784
    [Abstract] [Full Text] [Related]

  • 16. Identification of the N-glycosylation sites on recombinant bovine CD38 expressed in Pichia pastoris: their impact on enzyme stability and catalytic activity.
    Muller-Steffner H, Kuhn I, Argentini M, Schuber F.
    Protein Expr Purif; 2010 Apr 01; 70(2):151-7. PubMed ID: 19818407
    [Abstract] [Full Text] [Related]

  • 17. Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.
    Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE.
    Biochemistry; 2008 Mar 18; 47(11):3484-92. PubMed ID: 18293939
    [Abstract] [Full Text] [Related]

  • 18. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Unalp A, Altiok E, Uran N, Oztürk A, Yüksel S.
    J Trop Pediatr; 2008 Jun 18; 54(3):208-10. PubMed ID: 17999961
    [Abstract] [Full Text] [Related]

  • 19. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA, Akin H, Onay H, Vahabi A, Ozkinay F.
    Fetal Pediatr Pathol; 2012 Aug 18; 31(4):236-9. PubMed ID: 22468686
    [Abstract] [Full Text] [Related]

  • 20. Directed evolution and structural analysis of N-carbamoyl-D-amino acid amidohydrolase provide insights into recombinant protein solubility in Escherichia coli.
    Jiang S, Li C, Zhang W, Cai Y, Yang Y, Yang S, Jiang W.
    Biochem J; 2007 Mar 15; 402(3):429-37. PubMed ID: 17121498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.